91名健康参与者血清9种酶生物学变异估计
欧洲生物学变异研究对91名健康参与者连续10周采血,在6个中心按统一流程处理并集中检测9种血清酶。结果显示国家无影响,ALT、GGT和CK存在性别差异,并给出了各酶个体内和个体间生物学变异估计值,多数低于2014在线数据库。
要点
- 报告了9种血清酶的CVI和CVG估计值,如ALT为9.3%和28.2%。
- ALT、GGT和CK的生物学变异存在性别相关差异。
- 所有CVI及部分CVG低于2014在线生物学变异数据库。
核心结论
- 所有CVI和部分CVG估计值低于2014在线生物学变异数据库报告值。
- 基于生物学变异的分析性能规范可国际应用。
研究设计与样本
- 欧洲生物学变异研究,91名健康参与者(38男、53女,21-69岁)。
- 连续10周每周采血,6个欧洲实验室按统一预分析流程处理。
- 血清-80°C保存后于ADVIA 2400 Clinical Chemistry System单批双份检测。
主要发现
- 未发现国家来源对观察变异的影响。
- ALT、GGT和CK存在总体性别相关差异。
- ALT的CVI为9.3%、CVG为28.2%;AST为9.5%、20.3%;GGT为8.9%、41.7%。
- ALP的CVI为5.3%、CVG为24.9%;LDH为5.2%、12.6%;CK为14.5%、31.5%。
- 淀粉酶为6.8%、30.4%;胰腺α-淀粉酶为6.3%、24.9%;脂肪酶为7.7%、23.8%。
关键数值与推荐
- ALT:CVI 9.3%,CVG 28.2%。
- AST:CVI 9.5%,CVG 20.3%。
- GGT:CVI 8.9%,CVG 41.7%。
- ALP:CVI 5.3%,CVG 24.9%。
- LDH:CVI 5.2%,CVG 12.6%。
临床怎么用
- 可将本研究报告的CVI和CVG用于设定9种血清酶的分析性能规范。
- 解读ALT、GGT和CK结果时需考虑性别相关的生物学变异差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We sought to develop estimates of biological variation (BV) for 9 enzymes in blood serum as part of the European Biological Variation Study. METHODS: Ninety-one healthy study participants (38 male and 53 female, 21-69 years old) were phlebotomized in each of 10 consecutive weeks at 6 European laboratories. The same preanalytical sample-handling protocol was followed at each center before transport to San Raffaele Hospital, Milan, Italy, for analysis. Sera were stored at -80 °C before analysis in duplicate within a single run on an ADVIA 2400 Clinical Chemistry System (Siemens Healthcare) following a protocol designed to minimize analytical imprecision. Assay traceability was established using frozen sera with target values assigned by reference methods. The results were subjected to outlier analysis before CV-ANOVA to deliver valid BV estimates. Results for 9 enzymes were subsequently partitioned for graphical display allowing visual assessment of the effects of country of origin, sex, and age on BV estimates. RESULTS: We found no effect of country upon the observed variation, but overall sex-related differences were evident for alanine amino transferase (ALT), γ-glutamyl transferase (GGT), and creatine kinase (CK). The following estimates for within-subject BV (CVI) and between-subject BV (CVG), respectively, were obtained: ALT: 9.3%, 28.2%; aspartate aminotransferase: 9.5%, 20.3%; GGT: 8.9%, 41.7%; alkaline phosphatase : 5.3%, 24.9%; lactate dehydrogenase: 5.2%, 12.6%; CK: 14.5%, 31.5%; amylase: 6.8%, 30.4%; pancreatic α-amylase: 6.3%, 24.9%; and lipase (LIP): 7.7%, 23.8%. CONCLUSIONS: All CVI and some CVG estimates were lower than those reported in the online BV 2014 updated database. Analytical performance specifications derived from BV can be applied internationally.
引用
- Carobene A, Røraas T, Sølvik UØ, et al. Biological Variation Estimates Obtained from 91 Healthy Study Participants for 9 Enzymes in Serum. Clin Chem. 2017. PMID: 28428356. doi:10.1373/clinchem.2016.269811
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。